• Press Release/Announcement
  • Published May 2015

FDA cautions about dose confusion and medication errors for antibacterial drug Zerbaxa (ceftolozane and tazobactam).

Dosing information on drug labels should be clearly articulated to prevent confusion. This announcement raises awareness of a drug strength labeling change regarding active ingredients in the antibacterial drug Zerbaxa to improve dosing accuracy.

Back to Top